Online citations, reference lists, and bibliographies.
← Back to Search

Dendrimers As Nanostructured Therapeutic Carriers

Sabyasachi Maiti, Sougata Jana
Published 2017 · Chemistry

Cite This
Download PDF
Analyze on Scholarcy
Share
The unique features of dendrimers, such as their high degree of branching, multivalency, globular architecture, and well-defined molecular weight, make them promising carriers for the delivery of therapeutics. Dendrimer nanostructures represent outstanding nanocarriers in medicine. Dendrimeric structures are of particular interest in the field of drug delivery due to their peculiar structural properties including controllable internal cavities bearing specific species for the encapsulation of guest drugs and external periphery with 3D multiple functional moieties for solubilization, conjugation of bioactive compounds and targeting molecules, and recognition purposes. In addition, the low polydispersity of dendrimers provides reproducible pharmacokinetic behavior. Polyamidoamine (PAMAM) dendrimers, polypropyleneimine dendrimers, and peptide-based dendrimers such as those based on polylysine have been tested as promising nanostructured carriers for the delivery small drug molecules and macromolecules. Despite their broad applicability, it is generally necessary to modify the surface amine groups of these dendrimers with neutral or anionic moieties to avoid the toxicity associated with their polycationic surfaces. In recent years, much effort has been devoted to the preparation of dendrimers that are designed to be highly biocompatible, biodegradable, and water-soluble. In the past decade, research has been increased on the design and synthesis of biocompatible dendrimers and their application in the field of drug and macromolecules delivery. Recent progress in ocular, oral, brain, and tumor drug targeting application using dendrimers is discussed herein.
This paper references
10.1021/mp400178m
Synergistically combined gene delivery for enhanced VEGF secretion and antiapoptosis.
Young-Wook Won (2013)
10.1016/j.ophtha.2010.01.052
Triamcinolone crystal size.
M. Kleinman (2010)
10.1016/j.nano.2011.08.018
Polyamidoamine dendrimer hydrogel for enhanced delivery of antiglaucoma drugs.
C. A. Holden (2012)
10.1016/j.jconrel.2014.03.012
Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy.
L. M. Kaminskas (2014)
10.1158/1535-7163.MCT-05-0325
Targeted delivery of methotrexate to epidermal growth factor receptor–positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates
G. Wu (2006)
10.1167/iovs.10-5388
Nanosized dendritic polyguanidilyated translocators for enhanced solubility, permeability, and delivery of gatifloxacin.
C. Durairaj (2010)
10.1016/J.EJMECH.2005.06.010
Dendrimers as potential drug carriers. Part I. Solubilization of non-steroidal anti-inflammatory drugs in the presence of polyamidoamine dendrimers.
Cheng Yiyun (2005)
10.1016/S0169-409X(98)00040-4
Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract.
Ponchel (1998)
10.1016/j.ijpharm.2010.04.027
Dendrimer toxicity: Let's meet the challenge.
K. Jain (2010)
10.1016/j.addr.2008.12.006
CpG oligodeoxynucleotide-based therapy of lymphoid malignancies.
G. Weiner (2009)
10.1038/35053110
Role for a bidentate ribonuclease in the initiation step of RNA interference
E. Bernstein (2001)
10.1016/j.jconrel.2015.04.039
Evaluation of dendrimer type bio-reducible polymer as a siRNA delivery carrier for cancer therapy.
Joung-Pyo Nam (2015)
10.2174/1566524014666140128114414
Glucocorticoids: structure, signaling and molecular mechanisms in the treatment of diabetic retinopathy and diabetic macular edema.
X. Zhang (2014)
10.1021/bc800065f
Simple modifications of branched PEI lead to highly efficient siRNA carriers with low toxicity.
A. Zintchenko (2008)
10.1016/J.MOLMED.2007.09.002
Signaling to NF-?B by Toll-like receptors
T. Kawai (2007)
10.1021/nn301282m
Size-dependent localization and penetration of ultrasmall gold nanoparticles in cancer cells, multicellular spheroids, and tumors in vivo.
K. Huang (2012)
10.1016/J.ADDR.2005.09.017
Dendrimers in gene delivery.
C. Dufès (2005)
10.1021/MP049886U
Biological evaluation of polyester dendrimer: poly(ethylene oxide) "bow-tie" hybrids with tunable molecular weight and architecture.
E. Gillies (2005)
10.1016/S0168-3659(99)00246-1
Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo.
N. Malik (2000)
10.1016/J.ADDR.2005.09.018
Dendrimers in biomedical applications--reflections on the field.
Sönke Svenson (2005)
10.1016/j.oraloncology.2010.07.001
Dendrimer-triglycine-EGF nanoparticles for tumor imaging and targeted nucleic acid and drug delivery.
Q. Yuan (2010)
10.1016/J.BIOMATERIALS.2006.07.046
The development of folate-PAMAM dendrimer conjugates for targeted delivery of anti-arthritic drugs and their pharmacokinetics and biodistribution in arthritic rats.
D. Chandrasekar (2007)
10.1038/mt.2011.207
Systemic administration of combinatorial dsiRNAs via nanoparticles efficiently suppresses HIV-1 infection in humanized mice.
J. Zhou (2011)
10.1167/IOVS.04-0761
Vascular endothelial growth factor reduced and connective tissue growth factor induced by triamcinolone in ARPE19 cells under oxidative stress.
S. Matsuda (2005)
10.2147/IJN.S43251
Chitosan-coated boron nitride nanospheres enhance delivery of CpG oligodeoxynucleotides and induction of cytokines
Huijie Zhang (2013)
10.1111/j.1750-3639.1991.tb00656.x
Neuropathology of Human Immunodeficiency Virus Infection
H. Budka (1991)
10.1016/j.jconrel.2014.06.006
Transferrin-bearing polypropylenimine dendrimer for targeted gene delivery to the brain.
Sukrut Somani (2014)
10.1021/JA048548J
Cytotoxicity, hemolysis, and acute in vivo toxicity of dendrimers based on melamine, candidate vehicles for drug delivery.
Hui-Ting Chen (2004)
10.1167/IOVS.07-0566
Triamcinolone acetonide-mediated oxidative injury in retinal cell culture: comparison with dexamethasone.
Hyewon Chung (2007)
10.1186/1479-5876-7-51
Physiologic upper limit of pore size in the blood-tumor barrier of malignant solid tumors
H. Sarin (2009)
10.1016/j.jconrel.2011.02.013
Bioreducible polymers with cell penetrating and endosome buffering functionality for gene delivery systems.
T. Kim (2011)
10.1016/j.biomaterials.2008.10.009
Arginine-grafted bioreducible poly(disulfide amine) for gene delivery systems.
Tae-Il Kim (2009)
10.1016/j.drudis.2007.11.002
Current and future ophthalmic drug delivery systems. A shift to the posterior segment.
Eva M. del Amo (2008)
10.1016/j.ejpb.2008.09.023
Dendrimers as versatile platform in drug delivery applications.
S. Svenson (2009)
10.1021/BC050184C
Synthesis and evaluation of novel dendrimers with a hydrophilic interior as nanocarriers for drug delivery.
R. S. Dhanikula (2006)
10.1016/j.jcis.2015.03.019
CREKA peptide-conjugated dendrimer nanoparticles for glioblastoma multiforme delivery.
J. Zhao (2015)
10.1016/J.IJPHARM.2006.11.047
In vitro evaluation of dendrimer prodrugs for oral drug delivery.
M. Najlah (2007)
10.1254/JJP.87.97
Brain drug targeting and gene technologies.
W. Pardridge (2001)
10.1111/j.1464-410X.2006.06425.x
Small interference RNA targeting heat‐shock protein 27 inhibits the growth of prostatic cell lines and induces apoptosis via caspase‐3 activation in vitro
P. Rocchi (2006)
10.1016/j.ajo.2010.02.006
RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027.
P. Kaiser (2010)
10.1021/BC010102U
Polyester dendritic systems for drug delivery applications: design, synthesis, and characterization.
H. Ihre (2002)
10.1186/1479-5876-7-1
Comparative study on the immunogenicity between an HLA-A24-restricted cytotoxic T-cell epitope derived from survivin and that from its splice variant survivin-2B in oral cancer patients
J. Kobayashi (2008)
10.1016/j.drudis.2010.01.009
Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications.
A. R. Menjoge (2010)
10.2174/138945011796818135
Evaluation of dendrimer safety and efficacy through cell line studies.
P. Kesharwani (2011)
RNA interference : RNA
G. J. Hannon (2002)
10.1016/S0142-9612(02)00445-3
In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis.
D. Fischer (2003)
10.1167/IOVS.05-0772
Toxicity of triamcinolone acetonide on retinal neurosensory and pigment epithelial cells.
R. Narayanan (2006)
10.1016/j.ejmech.2009.10.017
Designing dendrimers for ocular drug delivery.
G. Spataro (2010)
10.1016/j.biomaterials.2011.10.010
Dendrimer-based targeted intravitreal therapy for sustained attenuation of neuroinflammation in retinal degeneration.
R. Iezzi (2012)
10.1021/mp2006104
Efficient delivery of sticky siRNA and potent gene silencing in a prostate cancer model using a generation 5 triethanolamine-core PAMAM dendrimer.
Xiaoxuan Liu (2012)
10.1016/j.jconrel.2014.12.042
In vivo delivery of siRNA to the brain by carbosilane dendrimer.
Mª Jesús Serramía (2015)
10.1016/S0378-5173(98)00115-X
Enhancement of percutaneous absorption of ketoprofen: effect of vehicles and adhesive matrix
Young-Joo Cho (1998)
10.1167/IOVS.04-1051
Permeability of retinal pigment epithelium: effects of permeant molecular weight and lipophilicity.
L. Pitkänen (2005)
10.1016/j.nano.2011.05.013
A comparison of changes to doxorubicin pharmacokinetics, antitumor activity, and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systems.
L. M. Kaminskas (2012)
10.2147/IJN.S50911
Branched polyethylenimine-grafted-carboxymethyl chitosan copolymer enhances the delivery of pDNA or siRNA in vitro and in vivo
S. Park (2013)
10.1016/j.jconrel.2012.04.025
Dendrimer type bio-reducible polymer for efficient gene delivery.
H. Y. Nam (2012)
10.1016/j.colsurfb.2013.10.002
Drug delivery investigations of quaternised poly(propylene imine) dendrimer using nimesulide as a model drug.
E. Murugan (2014)
10.1016/j.biotechadv.2013.08.001
Structurally flexible triethanolamine-core poly(amidoamine) dendrimers as effective nanovectors to deliver RNAi-based therapeutics.
Xiaoxuan Liu (2014)
10.1038/jcbfm.2009.104
Brain-Targeting Mechanisms of Lactoferrin-Modified DNA-Loaded Nanoparticles
R. Huang (2009)
10.1038/nnano.2011.166
Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size.
H. Cabral (2011)
10.1002/ANIE.199001381
Starburst Dendrimers: Molecular‐Level Control of Size, Shape, Surface Chemistry, Topology, and Flexibility from Atoms to Macroscopic Matter
D. Tomalia (1990)
10.1016/J.JCONREL.2004.09.015
Poly(amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide.
Th F Vandamme (2005)
10.18388/ABP.2001_5127
Dendrimers: properties and applications.
B. Klajnert (2001)
10.1016/j.jconrel.2010.08.028
Barrier analysis of periocular drug delivery to the posterior segment.
V. Ranta (2010)
10.1016/J.BIOPHA.2016.01.002
CpG oligodeoxynucleotide-loaded PAMAM dendrimer-coated magnetic nanoparticles promote apoptosis in breast cancer cells.
N. T. Pourianazar (2016)
10.1002/rmv.711
HIV‐1 infection and neurocognitive impairment in the current era
M. Palacio (2012)
ReviewSignaling to NF-κB by Toll-like receptors
Taro Kawai (2007)
10.1002/JPS.21079
Dendrimers as drug carriers: applications in different routes of drug administration.
Y. Cheng (2008)
Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy.
Y. Boucher (1990)
10.1021/MA971199B
Rheology of Dendrimers. I. Newtonian Flow Behavior of Medium and Highly Concentrated Solutions of Polyamidoamine (PAMAM) Dendrimers in Ethylenediamine (EDA) Solvent
S. Uppuluri (1998)
10.1155/2013/732340
Dendrimeric Systems and Their Applications in Ocular Drug Delivery
B. Yavuz (2013)
10.1038/nature03121
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
J. Soutschek (2004)
10.1007/s11095-009-0042-9
New Techniques for Drug Delivery to the Posterior Eye Segment
E. Eljarrat-Binstock (2009)
10.2174/157016307783220503
Design, synthesis and potent pharmaceutical applications of glycodendrimers: a mini review.
Y. Li (2007)
10.1016/J.JCONREL.2007.09.004
Non-viral is superior to viral gene delivery.
Shyh-Dar Li (2007)
10.1158/0008-5472.CAN-06-4762
Dendrimer-modified magnetic nanoparticles enhance efficiency of gene delivery system.
Bifeng Pan (2007)
10.1016/j.jconrel.2008.05.016
Mechanistic investigation of poly(ethylene imine)-based siRNA delivery: disulfide bonds boost intracellular release of the cargo.
M. Breunig (2008)
10.1007/BF03257477
Erratum to: Nimesulide: an update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy
R. Davis (2012)
10.1021/JA00179A041
Photophysical investigation of starburst dendrimers and their interactions with anionic and cationic surfactants
G. Caminati (1990)
10.1002/jps.24588
In Vitro/In Vivo Evaluation of Dexamethasone--PAMAM Dendrimer Complexes for Retinal Drug Delivery.
B. Yavuz (2015)
10.1016/j.jconrel.2009.11.015
Tumor regression after systemic administration of a novel tumor-targeted gene delivery system carrying a therapeutic plasmid DNA.
Swati Koppu (2010)
10.1167/IOVS.02-1068
Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles.
Jean-Louis Bourges (2003)
10.1016/J.IJMM.2007.07.007
Structural requirements for uptake and recognition of CpG oligonucleotides.
K. Heeg (2008)
10.2165/11538400-000000000-00000
Carbosilane Dendrimers to Transfect Human Astrocytes with Small Interfering RNA Targeting Human Immunodeficiency Virus
J. Jiménez (2012)
10.1046/j.1471-4159.2001.00541.x
Restricted transport of anti‐transferrin receptor antibody (OX26) through the blood–brain barrier in the rat
T. Moos (2001)
10.1016/J.EJMECH.2005.03.009
Synthesis, characterization, activities, cell uptake and DNA binding of trinuclear complex: [{trans-PtCl(NH(3))}(2)mu-{trans-Pt(NH(3))(2-hydroxypyridine)-(H(2)N(CH(2))(6)NH(2))(2)]Cl(4).
H. Cheng (2005)
10.1016/j.ophtha.2009.11.002
The iris is a sponge: a cause of angle closure.
H. Quigley (2010)
10.1097/00003226-199811000-00002
The pathology of dry eye: the interaction between the ocular surface and lacrimal glands.
M. Stern (1998)
10.1007/s11095-007-9324-2
Drug Targeting to the Brain
W. Pardridge (2007)
10.1111/J.1600-0420.2007.00885.X
Topical and systemic absorption in delivery of dexamethasone to the anterior and posterior segments of the eye.
H. Sigurdsson (2007)
10.1211/jpp.57.12.0005
Size‐dependent disposition of nanoparticles and microparticles following subconjunctival administration
A. Amrite (2005)
10.1021/JS960298K
Study of the influence of both cyclodextrins and L-lysine on the aqueous solubility of nimesulide; isolation and characterization of nimesulide-L-lysine-cyclodextrin complexes.
G. Piel (1997)
10.1212/01.WNL.0000120551.38463.D9
Gene therapy of the brain
F. Schlachetzki (2004)
10.1002/(SICI)1097-4636(199601)30:1<53::AID-JBM8>3.0.CO;2-Q
Preliminary biological evaluation of polyamidoamine (PAMAM) Starburst dendrimers.
J. Roberts (1996)
10.2217/nnm.11.67
Dendrimer pharmacokinetics: the effect of size, structure and surface characteristics on ADME properties.
L. M. Kaminskas (2011)
10.1016/J.CEJ.2015.07.024
Preparation of graphene oxide/dendrimer hybrid carriers for delivery of doxorubicin
A. Siriviriyanun (2015)
10.1016/j.biomaterials.2009.06.026
Targeted intracellular codelivery of chemotherapeutics and nucleic acid with a well-defined dendrimer-based nanoglobular carrier.
Todd L Kaneshiro (2009)
10.1002/1521-3765(20010716)7:14<3095::AID-CHEM3095>3.0.CO;2-S
Synthesis and characterization of linear, hyperbranched, and dendrimer-like polymers constituted of the same repeating unit.
S. Merino (2001)
10.1016/S0378-5173(02)00623-3
The influence of surface modification on the cytotoxicity of PAMAM dendrimers.
R. Jevprasesphant (2003)
10.1016/j.drudis.2007.10.021
Nanotechnology in ocular drug delivery.
S. Sahoo (2008)
10.1039/C3RA45408H
Carbosilane cationic dendrimers synthesized by thiol–ene click chemistry and their use as antibacterial agents
Elena Fuentes-Paniagua (2014)
10.1016/j.ejpb.2015.02.013
Intracellular delivery of dendrimer triamcinolone acetonide conjugates into microglial and human retinal pigment epithelial cells.
S. Kambhampati (2015)
10.1167/iovs.10-6058
Mechanisms underlying benzyl alcohol cytotoxicity (triamcinolone acetonide preservative) in human retinal pigment epithelial cells.
Yi-Sheng Chang (2011)
10.1016/j.nbd.2009.07.028
Approaches to transport therapeutic drugs across the blood–brain barrier to treat brain diseases
R. Gabathuler (2010)
10.3109/03639041003610799
Preparation and characterization of puerarin–dendrimer complexes as an ocular drug delivery system
Wenjun Yao (2010)
10.2741/2774
Pharmaceutical applications of dendrimers: promising nanocarriers for drug delivery.
Y. Cheng (2008)
10.1016/J.PHARMTHERA.2004.08.001
Delivery of therapeutic agents to the central nervous system: the problems and the possibilities.
D. Begley (2004)
10.4155/tde.13.21
Transferrin and the transferrin receptor for the targeted delivery of therapeutic agents to the brain and cancer cells.
C. Dufès (2013)
10.1073/PNAS.90.7.2618
Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery.
U. Bickel (1993)
10.1002/CHEM.200305386
A surface-modified dendrimer set for potential application as drug delivery vehicles: synthesis, in vitro toxicity, and intracellular localization.
S. Fuchs (2004)
[Chitosan-siRNA complex nanoparticles for gene silencing].
Xiudong Liu (2010)
10.1016/J.ADDR.2005.09.014
Targeted drug delivery with dendrimers: comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex.
A. Patri (2005)
10.2174/157016206777709447
The blood-brain barrier in neuroAIDS.
W. Banks (2006)
10.1016/J.EJMECH.2006.01.001
Dendrimers as potential drug carriers. Part II. Prolonged delivery of ketoprofen by in vitro and in vivo studies.
Man Na (2006)
10.1227/00006123-199408000-00016
Receptor-mediated transport of therapeutics across the blood-brain barrier.
P. Friden (1994)
10.1016/j.chembiol.2011.12.008
RNA-based therapeutics: current progress and future prospects.
J. Burnett (2012)
10.1016/j.biomaterials.2012.02.004
A dual-targeting nanocarrier based on poly(amidoamine) dendrimers conjugated with transferrin and tamoxifen for treating brain gliomas.
Y. Li (2012)
10.1211/jpp.58.11.0010
Investigations on the toxicological profile of functionalized fifth‐generation poly(propylene imine) dendrimer
H. Agashe (2006)
10.1016/0169-409X(95)00012-V
Ocular drug delivery conventional ocular formulations
John C. Lang (1995)
10.1021/ja101524z
Solid-state NMR reveals the hydrophobic-core location of poly(amidoamine) dendrimers in biomembranes.
Pieter E. S. Smith (2010)
10.1016/S1359-6446(04)03276-3
Dendrimers and dendritic polymers in drug delivery.
E. Gillies (2005)
10.1038/nrg908
Gene silencing in mammals by small interfering RNAs
Michael T. McManus (2002)
10.1016/J.JCONREL.2003.12.006
The use of a dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability.
A. D’Emanuele (2004)
10.1016/S0092-8674(04)00258-2
A Dicer-2-Dependent 80S Complex Cleaves Targeted mRNAs during RNAi in Drosophila
John W Pham (2004)
10.1038/312162A0
Transferrin receptor on endothelium of brain capillaries
W. Jefferies (1984)
10.1295/POLYMJ.17.117
A New Class of Polymers: Starburst-Dendritic Macromolecules
D. Tomalia (1985)
10.1073/PNAS.95.8.4607
Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment.
S. Hobbs (1998)
10.1016/j.jconrel.2010.08.027
To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery.
F. Danhier (2010)
10.1016/j.carbpol.2013.07.021
Polyamidoamine dendrimer conjugated chitosan nanoparticles for the delivery of methotrexate.
Zhen-Hua Leng (2013)
10.1016/j.ejpb.2015.08.001
Tumor targeting using polyamidoamine dendrimer-cisplatin nanoparticles functionalized with diglycolamic acid and herceptin.
A. Kesavan (2015)
10.2337/db07-0982
Intravitreal Triamcinolone Acetonide Inhibits Breakdown of the Blood-Retinal Barrier Through Differential Regulation of VEGF-A and Its Receptors in Early Diabetic Rat Retinas
X. Zhang (2008)
10.1016/J.ADDR.2005.09.019
Dendrimer biocompatibility and toxicity.
R. Duncan (2005)
10.1021/BM050802S
Dendrimers: novel polymeric nanoarchitectures for solubility enhancement.
U. Gupta (2006)
10.1016/j.biomaterials.2011.12.019
Tumor regression following intravenous administration of a tumor-targeted p73 gene delivery system.
Fanny Lemarié (2012)
10.1016/j.ijpharm.2015.11.025
Integrin-mediated active tumor targeting and tumor microenvironment response dendrimer-gelatin nanoparticles for drug delivery and tumor treatment.
Guanlian Hu (2015)
10.1038/nbt1051
Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy
Dongho Kim (2005)
10.1021/bc400226b
Tumor-targeting transferrin nanoparticles for systemic polymerized siRNA delivery in tumor-bearing mice.
J. Y. Yhee (2013)
10.1016/j.nano.2014.05.008
Targeted delivery of Dicer-substrate siRNAs using a dual targeting peptide decorated dendrimer delivery system.
Xiaoxuan Liu (2014)
10.1126/SCIENCE.8134834
Functional polymers and dendrimers: reactivity, molecular architecture, and interfacial energy.
J. M. Frechet (1994)
10.1677/ERC.0.0080003
The epidermal growth factor receptor as a target for cancer therapy.
J. Mendelsohn (2001)
10.1016/j.jconrel.2015.11.004
Lipid-dendrimer hybrid nanosystem as a novel delivery system for paclitaxel to treat ovarian cancer.
Yuanjie Liu (2015)
10.1038/nature08956
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
M. Davis (2010)
10.2147/IJN.S23696
Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy
E. Miele (2012)
10.1016/j.ijpharm.2012.10.024
Delivery of paclitaxel across cellular barriers using a dendrimer-based nanocarrier.
H. M. Teow (2013)



Semantic Scholar Logo Some data provided by SemanticScholar